Posters

      Decreased Levels of Biomarkers of Exposure in Smokers Switching to Carbon-Heated Tobacco Product 1.2 compared with those who continued to smoke: A Randomized, Controlled, Open-Label 90-Day Exposure Study

      Tran, C. T.; Bosilkovska, M.; de La Bourdonnaye, G.; Blanc, N.; Benzimra, M.; Ancerewicz, J. Ancerewicz.; Haziza, C.; Lüdicke, F.

      Conference date
      Feb 22, 2019
      Conference name
      Society for Research on Nicotine and Tobacco (SRNT) 2019
      Link to more information
      Topic
      Summary

      Background: In addition to smoking cessation (SC) programs, tobacco harm reduction strategies include switching from cigarettes to reduced-risk alternatives in smokers who wish to continue to smoke. The Carbon Heated Tobacco Product (CHTP) 1.2, similar in appearance to a cigarette, replicates the smoking ritual while generating a nicotine-containing aerosol by heating tobacco instead of burning it and is currently being assessed for its harm reduction potential compared with cigarettes. Methods: We conducted a randomized, controlled, open-label, two-arm parallel group study in 120 healthy adult European smokers who either switched from cigarette smoking to CHTP 1.2 (CHTP 1.2 group; N=80) or continued to smoke cigarettes (cigarette group; N=40) for five days in a confined setting followed by 85 days in an ambulatory setting. The study aimed to demonstrate reduction in the exposure to 14 harmful and potentially harmful constituents and to evaluate the effects on clinical risk endpoints (CRE) indicative of mechanistic pathways underlying the development of smokingrelated diseases and the safety profile between the two groups. Results: Significant reductions in all biomarkers of exposure (BoExp) were observed in the CHTP 1.2 group on Day 5 (40.2% to 94.9%) and sustained throughout the 85-day ambulatory period (36.3% to 92.9%) when compared with the cigarette group. In addition, changes in CREs involved in lipid metabolism, inflammation, endothelial dysfunction, and platelet activation were favorable in the CTHP 1.2 group, consistent with those observed in the literature upon SC. Lung function parameters exhibited no differences between the two groups, as lung function changes require a longer period. CHTP 1.2 was well accepted and delivered satisfactory nicotine levels. Most of the adverse events were assessed as mild or moderate; none led to discontinuation of the randomized subjects. Conclusions: Switching from cigarettes to CHTP 1.2 resulted in significant reductions in BoExp levels that were associated with favorable changes in some CREs. These results provide evidence that CHTP 1.2 likely reduces the risk of developing smoking-related diseases compared with cigarettes.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.